Regeneron Pharmaceuticals, Inc. (REGN)

461.60 +11.03 (+2.45%) As of 12:11PM EST. Market open.

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
http://www.regeneron.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9,123

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Leonard S. Schleifer	Co-Founder, Pres, CEO & Exec. Director	4.77M	111.22M	1953
Dr. George D. Yancopoulos	Co-Founder, Pres & Chief Scientific Officer & Director	3.98M	87.3M	1960
Mr. Robert E. Landry Jr.	Exec. VP of Fin. & CFO	1.56M	N/A	1964
Dr. Andrew J. Murphy	Exec. VP of Research	1.29M	7.93M	1958
Mr. Daniel P. Van Plew	Exec. VP and GM of Industrial Operations & Product Supply	1.46M	N/A	1973
Ms. Patrice Gilooly	Sr. VP of Quality Assurance & Operations	N/A	N/A	N/A
Mr. Christopher R. Fenimore	Sr. VP, Head of Accounting & Controller	N/A	N/A	1971
Mr. Gerald Underwood	Sr. VP of Technical Operations	N/A	N/A	N/A
Mr. Bob McCowan	Sr. VP of IT & Chief Information Officer	N/A	N/A	N/A
Justin Holko	VP of Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Corporate governance

Regeneron Pharmaceuticals, Inc.’s ISS governance QualityScore as of 2 December 2020 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.